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Abstract
Background Histological findings from primary kidney biop-
sies were correlated with patient outcomes in a national cohort
of paediatric Henoch–Schönlein nephritis (HSN) patients.
Methods Primary kidney biopsies from 53 HSN patients were
re-evaluated using the ISKDC (International Study of Kidney
Disease in Children) classification and a modified semiquan-
titative classification (SQC) that scores renal findings and also
takes into account activity, chronicity and tubulointerstitial
indices. The ISKDC and SQC classifications were evaluated
comparatively in four outcome groups: no signs of renal dis-
ease (outcome A, n = 27), minor urinary abnormalities (out-
come B, n = 18), active renal disease (outcome C, n = 3) and
renal insufficiency, end-stage renal disease or succumbed due
to HSN (outcome D, n = 5). For the receiver operating char-
acteristic and logistic regression analyses, outcomes A and B
were considered to be favourable and outcomes C and D to be
unfavourable. The median follow-up time was 7.3 years.
Results The patients with an unfavourable outcome (C and
D), considered together due to low patient numbers, had sig-
nificantly higher total biopsy SQC scores and activity indices
than those who had a favourable one (groups A and B). The
chronicity and tubulointerstitial indices differed significantly
only between group C + D and group A. The difference in
areas under the curve between the total biopsy SQC scores
and ISKDC findings was 0.15 [p = 0.04, normal-based 95%
confidence interval (CI) 0.007–0.29, bias-controlled 95% CI
−0.004 to 0.28].
Conclusions Our results suggest that the modified SQC is
more sensitive than ISKDC classification for predicting the
outcome in HSN cases.
Keywords Children .Glomerulonephritis . Histology .Renal
biopsy . Semiquantitative . Vasculitis
Introduction
Henoch–Schönlein purpura (HSP) is the most common form
of vasculitis in children [1]. Although the prognosis is gener-
ally good, severe nephritis (HSN) remains the major cause of
morbidity and mortality among children with HSP [2]. In a
systematic review of 12 studies involving 1133 unselected
patients with HSP, 34.2% of the patients were found to have
had renal involvement [3]. The outcome and severity of HSN
is difficult to predict due to the wide variability in its signs and
symptoms [4]. A kidney biopsy has therefore remained the
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gold standard for evaluating the severity of HSN and the as-
sociated prognosis.
The classical grading system for renal biopsies in cases of
HSN is the International Study of Kidney Disease in Children
(ISKDC) classification [5], which is based mainly on the pres-
ence and number of affected glomeruli. However, the ISKDC
classification has been criticized on the grounds that it ignores
tubulointerstitial and vascular changes [4, 6]. This has led to
the introduction of various semiquantitative classifications.
We have developed a practical and sensitive histological semi-
quantitative classification (SQC), as used by Ronkainen et al.
for the evaluation of immunoglobulin A (IgA) nephropathy
[7].
The aim of the study reported here was to evaluate the
feasibility of the modified SQC in cases of HSN. To this
end, we compared the ISKDC and SQC classifications for
their ability to predict the clinical outcome in a cohort of
HSN patients. Clinical variables at the time of the biopsy were
also evaluated relative to patient outcomes.
Methods
The study population consisted of patients recruited for our
previous HSN projects at Helsinki University Hospital (2000–
2010) and Oulu University Hospital (1985–2005) and for a
nationwide HSN cohort study (1999–2006) [8] (Electronic
Supplementary Material Table S1). A total of 53 patients (24
boys, 29 girls) with biopsy-proven HSN and aged <17 years at
the time of diagnosis were identified from our patient register.
Their medical histories and laboratory results were retrieved
and analysed retrospectively from the onset of HSP until the
latest control visit, with a focus on evaluating the clinical
course of the disease over time in terms of symptoms, labora-
tory findings, treatment administered and resolution of symp-
toms achieved. We also collected information on the duration
of time elapsing from the first symptoms to the first biopsy
and from the biopsy to the initiation of possible treatment.
Renal function was evaluated by calculating the estimated
glomerular filtration rate (eGFR) using the Bedside
Schwartz equation [9] or the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) equation for patients
aged >18 years [10]. Proteinuria was defined as urine protein
excretion of >200 mg/24 h measured from 24-h urine collec-
tion (dU-Prot) or calculated from a spot urine sample using
estimated protein excretion [11]. Haematuria was defined as
>5 red blood cells (RBCs)/high-power field, >20 RBCs/10E6/
L, or a positive dipstick test (+ to +++).
The outcome for each patient was assessed at the time of
the last control visit, using a modified version of the grading
system reported by Goldstein et al. [12] and Ronkainen et al.
[13]. The clinical outcome was graded as: A = no signs of
renal disease in laboratory tests and normal blood pressure;
B = minor urinary abnormalities (microscopic haematuria
and/or protein/creatinine ratio of 21–200 mg/mmol) or anti-
proteinuric/anti-hypertensive medication in use, normal blood
pressure and GFR; C = protein/creatinine ratio of ≥200 mg/
mmol or hypertension [blood pressure (BP) > 160/
95 mmHg] or immunosuppressive medication in use; D = re-
duced renal function (GFR <60 ml/min/1.73 m2). Grades A
and B were both considered to be favourable outcomes but
were analysed separately while grades C and D were consid-
ered to be unfavourable outcomes and were analysed together
as group C + D due to the small number of patients in each
group (3 and 5 patients in groups C and D, respectively).
The clinical characteristics at the time of the biopsy in all
patients and in different outcome groups separately are pre-
sented in Table 1. At the end of the follow-up (median
7.3 years), there were 27 patients (51%) in outcome group
A, 18 (34%) in group B, three (6%) in outcome group C and
five (9%) in outcome group D. One patient in group C was
hypertensive despite being treated with two anti-hypertensive
drugs, one patient had nephrotic-range proteinuria and one
was receiving cyclosporine (CyA) due to persistent protein-
uria. One patient in group D had died of an HSN-related hy-
pertensive crisis [14], two had undergone kidney transplanta-
tions (14.4 and 5.7 years after the initial diagnosis) and two
had developed renal insufficiency (estimated GFR 37 and
45 ml/min/1.73 m2).
Of the 53 patients enrolled in the study, 38 (72%) had
received immunosuppressive treatment based on kidney biop-
sy findings. Briefly, most patients with ISKDC grade ≥ III and
some patients with ISKDC grade II were treated with methyl-
prednisolone pulses followed by oral prednisolone, CyA, cy-
clophosphamide, azathioprine or mycophenolate mofetil in
various combinations. Angiotensin-converting enzyme inhib-
itors (ACEs) and angiotensin-receptor blockers (ARBs) were
typically used as additional treatments to control proteinuria.
Some patients with ISKDC grade II and with ISKDC grade III
and non-nephrotic proteinuria received only ACEs and/or
ARBs. All patients with an ISKDC grade higher than III had
received immunosuppressive treatment. The ISKDC grades
refer to the re-evaluation, but the treatment decisions were
based on the original biopsy report. Oral prednisolone or pred-
nisone for extrarenal symptoms was prescribed in 26 cases
(49%) and ACEs and/or ARBs in 45 cases (85%).
All of the kidney biopsy samples were re-analysed by ex-
perienced renal pathologists (P.H. and J.L. at Helsinki
University Hospital and H.A.-H. at Oulu University
Hospital), who were blinded to the patients’ histories. The
biopsies were then classified using both the ISKDC classifi-
cation (Table 2) and the modified SQC (Table 3) in which the
glomerular, tubular, interstitial and vascular findings were
scored separately, giving a maximum (total biopsy) score of
26 points. The SQC can also be divided into an activity index
(maximum 9 points), chronicity index (maximum 16 points)
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and focal or diffuse mesangial proliferation (0 points for focal,
1 point for diffuse). In addition, a tubulointerstitial index
(combining all tubular and interstitial parameters from the
SQC, including both active and chronic changes, maximum
5 points) was calculated. Inter-rater reliability (IRR) was cal-
culated from a randomly chosen subset of ten biopsies which
were evaluated and scored with SQC by renal pathologists.
Statistical analyses
The statistical analyses were performed using IBM SPSS
for Windows, version 22 (IBM Corp, Armonk, NY). In
addition, areas under the curve (AUC) were compared
using Stata 12.1 (StataCorp LP, College Station, TX) in
the form of the Stata user-written module [15]. A total of
5000 bootstrap resamples were drawn to estimate the 95%
confidence intervals (95% CI) of the AUC for histological
classification systems and their AUC difference. For the
purposes of AUC analysis, outcome grades A and B were
coded as non-diseased and grades C and D as diseased.
Youden indices (optimal cut-off points when sensitivity
and specificity are given equal weight) were calculated
from receiver operating characteristic (ROC) curves [16].
Histological classifications were also compared using lo-
gistic regression and reported in terms of odds ratios, pro-
file likelihood CIs and Akaike Information Criterion
(AIC) (lower AIC values indicate better model fitting).
IRR was assessed using two-way mixed, absolute agree-
ment intra-class correlation coefficients (ICC) . Cut-offs
for ICC are as follows: poor for <0.4, fair for 0.4 – 0.59,
good for 0.6–0.74 and excellent for 0.75–1.0 [17].
Continuous variables with a normal distribution are re-
ported as means with standard deviation, and data that
did not show a normal distribution were reported as me-
dians with their interquartile range (IQR). Categorical var-
iables are presented as numbers and percentages. Missing
values are treated as missing in the analyses. Comparisons
of multiple groups were performed with the Kruskal–
Wallis test, and if a difference was found among the
groups tested, a post hoc analysis was performed with
Table 2 The grading system of the International Study of Kidney
Disease in Children classification for renal biopsies in cases of
Henoch–Schönlein nephritis
ISKDC grade Description
Grade I Minimal changes
Grade II Mesangial proliferation
Grade III Crescents < 50% of the glomeruli; A: Focal, B: Diffuse
Grade IV Crescents 50–75% of the glomeruli; A: Focal, B: Diffuse
Grade V Crescents > 75% of the glomeruli
Grade VI Membranoproliferative glomerulonephritis
ISKDC, The International Study of Kidney Disease in Children
Table 1 Clinical characteristics of the patients at the time of the biopsy
Clinical characteristics All patients (n = 53) Outcome group A (n = 27) Outcome group B (n = 18) Combined outcome
group C +D (n = 8)
p valuea
Gender (female:male) 29:24 13:14 12:6 4:4 0.49b
Age (years) 10.2 ± 3.3 9.3 ± 3.3 11.0 ± 3.2 11.8 ± 2.3 0.073c
Follow-up (years) 7.3 (5.4–9.5) 6.6 (5.2–8.6) 7.0 (5.1–9.4) 10.2 (7.3–12.5) 0.22c
Plasma creatinine (μmol/L) 50.0 (43.0–56.0) 45.0 (40.0–54.5) 52.5 (45.0–58.0) 54.0 (49.5–83.0) 0.094c
eGFR (ml/min/1.73 m2) 106 ± 27 111 ± 24 104 ± 27 95 ± 33 0.36c
dU-Prot (g/day) 2.6 (1.1–6.3) 2.6 (1.1–5.4) 2.1 (0.3–4.1) 10.2 (5.5–12.9) 0.018c
Plasma albumin (g/L) 29.3 (23.7–38.3) 33.0 (25.2–38.0) 32.9 (28.0–40.0) 20.5 (18.8–29.0) 0.12c
Patients with hematuria 100% 100% 100% 100%
Systolic BP (mmHg) 116.8 ± 13.8 116.5 ± 15.2 110.8 ± 8.2 130.1 ± 8.7 0.002c
Diastolic BP (mmHg) 68.1 ± 12.9 68.7 ± 13.8 65.4 ± 11.5 71.8 ± 12.4 0.36c
Time from onset of nephritis to
biopsy (days)
57 (28–106) 56 (32–87) 75 (35–106) 29 (18–141) 0.36c
Time from biopsy to treatment (days) 8 (2–23) 7 (3–15) 11 (8–32) 7 (2–23) 0.49c
Treatment of nephritis with steroids or
other immunosuppressives
38 (72%) 19 (70%) 11 (61%) 8 (100%) 0.12b
Values in table are presented as a number with/without the percentage in parenthesis, the mean ± standard deviation or the median with the interquartile
range in parenthesis, as appropriate
eGFR, Estimated glomerular filtration rate; dU-Prot, 24-h urine protein excretion; BP, blood pressure
a Comparison between outcome groups A, B and combined group C +D
b Fisher’s exact test
c Kruskal–Wallis test
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the Mann–Whitney U test using the Bonferroni correction
and exact p values. Comparisons of categorical variables
were performed with Fisher’s exact test and also present-
ed with relative risk (RR) and 95% CI data. Statistical
significance was set at p < 0.05.
Results
The distribution of the ISKDC grades and SQC scores
with respect to the four outcome groups are presented in
Tables 4 and 5, respectively . The total biopsy score (p =
0.001), activity index (p = 0.003), chronicity index (p =
0.030) and tubulointerstitial index (p = 0.022) differed sig-
nificantly between the three outcome groups (A, B, C +
D; Table 5; Fig. 1). According to the post hoc analysis,
the total biopsy score and activity index were significantly
higher in outcome group C + D than in group A
(Bonferroni adjusted p <0.001 for the total biopsy score
and p = 0.001 for the activity index) or group B
(Bonferroni adjusted p = 0.004 for the total biopsy score
and p = 0.008 for the activity index). The corresponding
differences in the chronicity and tubulointerstitial indices
were significant only between group C + D and group A
(Bonferroni adjusted p = 0.009 for chronicity index and
p = 0.013 for tubulointerstitial index), but not between
group C + D and group B (Bonferroni adjusted p = 0.37
for chronicity index and p = 0.33 for tubulointerstitial in-
dex). There were no statistically significant differences in
any of the four biopsy categories of SQC between
Table 3 Histological scoring
system of the modified
semiquantitative classification for
renal biopsies in cases of
Henoch–Schönlein nephritis
Modified SQC Description Score
Glomerular changes
Lobulation Active 0–1a





Fibrinous thrombosis Active 0–3b
Global sclerosis Chronic 0–3b
Segmental sclerosis Chronic 0–2c
Tubular changes
Thickening of the basement membrane Chronic 0–1a
Complete atrophy Chronic 0–1a
Tubular dilatation Active 0–1a
Interstitial changes
Fibrosis Chronic 0–1a
Inflammation OR periglomerular inflammation Chronic 0–1a
Capillary changes
Arteriosclerosis OR arterial inflammation Chronic 0–1a
Focal or diffuse mesangial proliferation 0 for focal, 1 for diffuse
SQC, Semiquantitative classification
a 0 = absent; 1 = present
b 0 = 0% of glomeruli affected; 1 = 0–5% of glomeruli affected; 2 = 5–10% of glomeruli affected; 3= >10% of
glomeruli affected
c 0 = 0% of glomeruli affected; 1 = 0–5% of glomeruli affected; 2= >5% of glomeruli affected
Table 4 International Study of
Kidney Disease in
Children(ISKDC) grades in all
patients and separately according






group A (n = 27)
Outcome
group B (n = 18)
Outcome
group C (n = 3)
Outcome
group D (n = 5)
II 18 10 8 0 0
III 32 16 10 3 3
IV 2 1 0 0 1
V 1 0 0 0 1
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outcome groups A and B (Bonferroni adjusted p >0.99 for
the total biopsy score, p > 0.99 for the activity index,
p > 0.99 for the chronicity index and p = 0.71 for the
tubulointerstitial index). The median number of glomeruli
was 22 (IQR 12 – 31).
Eighteen biopsies (34%) were classified as ISKDC grade
II, 32 biopsies (60%) as ISKDC grade III, two biopsies (4%)
as ISKDC grade IV and one biopsy (2%) as ISKDC grade V.
None of the patients with ISKDC grade II and six of the 32
(19%) patients with ISKDC grade III had an unfavourable
Table 5 Semiquantitative classification (SQC) scores in all patients and separately according to long-term renal outcomes
SQC categories All patients (n = 53) Outcome group A (n = 27) Outcome group B (n = 18) Combined outcome
group C +D (n = 8)
p valuea
Total biopsy score 7.0 (4.0–11.0) 6.0 (4.0–8.5) 6.0 (4.0–9.0) 13.0 (11.0–14.5) 0.001b
Activity index 4.0 (2.0–6.0) 3.0 (2.0–4.0) 3.0 (2.0–5.0) 7.5 (6.0–8.0) 0.003b
Chronicity index 3.0 (0–4.0) 2.0 (0–3.0) 2.5 (0–5.0) 4.0 (3.5–5.5) 0.030b
Tubulointerstitial index 0 (0–1.0) 0 (0–1.0) 0 (0–1.0) 1 (0.5–2.0) 0.022b
a Comparison was between outcome groups A, B and combined group C +D
bKruskal-Wallis test
Fig. 1 Box-plots of all semiquantitative classification biopsy categories with respect to the three outcome groups: a total biopsy score, b activity index, c
chronicity index, d tubulointerstitial index
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outcome. Of the two patients with ISKDC grade IV, one had a
favourable outcome and the other an unfavourable one. The
only patient with ISKCD grade V had an unfavourable
outcome.
The true positive rate (sensitivity) and false positive
rate (1 − specificity) of the biopsy classifications were
compared using ROC curve analyses and by calculating
the respective AUC values (Fig. 2). The total biopsy score
had the largest AUC, 0.912 (95% CI 0.824–1.0), followed
by the activity index, 0.878 (95% CI 0.780–0.975), the
chronicity index, 0.776 (95% CI 0.647–0.906) and the
ISKDC, 0.765 (95% CI 0.607–0.923). The AUC differ-
ence between the total biopsy score and ISKDC classifi-
cation was 0.15 (p = 0.04, normal-based 95% CI 0.007–
0.29, bias-corrected 95% CI −0.004 to 0.28). The Youden
index for the total biopsy score was 0.72, and the corre-
sponding cut-off point was 10.5. When this cut-off point
was applied to the patient outcomes, seven of the 14
(50%) patients with a total biopsy score of ≥11 had an
unfavourable outcome, while only one of 39 (3%) patients
with a total biopsy score of ≤10 had an unfavourable
outcome (7/14 vs. 1/39; RR 19.5, 95% CI 2.6–144.7,
Fisher’s exact test p <0.001). For ISKDC, the Youden
index was 0.40, and the corresponding cut-off point was
2.5. When this cut-off point was used, eight of the 35
patients with ISKDC grade III or higher (23%) and zero
of the 18 of the patients with ISKDC grade II or lower
(0%; 0.5 was added to all cells to calculate the RR) had an
unfavourable outcome (8/35 vs. 0/18; RR 9.0, 95% CI
0.5–147.2, Fisher’s exact test p = 0.040). We also com-
pared the biopsy classifications using univariate logistic
regression (Table 6), in which the fit of the model was
tested by calculating AIC values; the total biopsy score of
the SQC had the lowest value, 30.8, while that for the
ISKDC was 38.8. The IRR of the SQC classification,
when assessed with ICC, was 0.43 for single measures
and 0.61 for average measures.
There were statistically significant differences in urine pro-
tein excretion between the outcome groups (p = 0.018) at the
time of the biopsy (Table 1; Fig. 3). Post hoc pairwise com-
parisons showed that dU-Prot at the time of the first biopsy
was significantly higher in combined group C + D than that in
group A (Bonferroni adjusted p = 0.036) or B (Bonferroni
Fig. 2 Receiver operating characteristic (ROC) curves for the total biop-
sy score, International Study of Kidney Disease in Children (ISKDC)
classification, activity index and chronicity index. For the purpose of
the ROC analyses outcome groups A and B were coded as non-
diseased and C and D as diseased. Areas under the curve (AUC) for the
total biopsy score, ISKDC classification, activity index and chronicity
index were 0.912 [95% confidence interval (CI) 0.824–1.0], 0.765
(95% CI 0.607–0.923), 0.878 (95% CI 0.780–0.975) and 0.776 (95%
CI 0.647–0.906), respectively. The AUC difference between the total
biopsy score and ISKDC classification was 0.147 (normal-based 95%
CI 0.007–0.287, bias-corrected 95% CI −0.004 to 0.281), that between
the activity index and ISKDC classification was 0.112 (normal-based
95% CI −0.021 to 0.246, bias-corrected 95% CI −0.028 to 0.241) and
that between the chronicity index and ISKDC classification was 0.011
(normal-based 95% CI −0.162 to 0.184, bias-corrected 95% −0.168 to
0.178). aROC curves for the total biopsy score and ISKDC classification,
b ROC curves for the activity index and chronicity index
Table 6 Comparisons between the International Study of Kidney
Disease in Children (ISKDC) classification and Semiquantitative













SQC—Activity index 35.1 1.94 1.33–3.28
SQC—Chronicity index 43.4 1.42 1.06–1.99
ISKDC classification 38.8 11.32 2.2–217.24
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adjusted p = 0.026), whereas there was no difference in dU-
Prot between groups A and B (Bonferroni adjusted p >0.99).
Also, systolic blood pressure at the time of the biopsy was
higher in group C +D than in group A (Bonferroni adjusted
p = 0.025) or B (Bonferroni adjusted p <0.001) (Table 1;
Fig. 3). Again, groups A and B had a similar systolic blood
pressure (Bonferroni adjusted p = 0.64). No statistically sig-
nificant differences between the three outcome groups were
found in any of the other laboratory or demographic parame-
ters studied here (Table 1).
Discussion
The correlation between primary kidney biopsy findings and
patient outcome was evaluated here in a nationwide cohort of
paediatric HSN patients. Re-evaluation of the biopsy samples
using both the ISKDC classification and a modified SQC
scoring system showed the SQC to be more coherent and
more sensitive in terms of predicting patient outcomes. In
addition, proteinuria and systolic blood pressure at the time
of diagnosis were found to correlate with the outcome. The
proportion of patients with a poor outcome in our series was
eight in 53 (15%) patients which is slightly lower than that
reported in other surveys with similar or shorter follow-up
times [18, 19]. One explanation of this difference may be that
most of the patients in our cohort had received immunosup-
pressive and/or antiproteinuric treatment for nephritis.
The ISKDC classification was published in 1977 and has
been used widely as a grading system for HSN and IgA ne-
phropathy. It has nevertheless been criticized for taking only
mesangial proliferation and the percentage of crescentic glo-
meruli into consideration and ignoring other glomerular and
tubulointerstitial parameters [4, 6]. We have previously shown
in an HSP cohort that patients with a low (grades I and II)
ISKDC grade in their first biopsy may have an unfavourable
long-term outcome [13]. This suggests that evaluation of the
activity and chronicity components separately is important as
early treatment is warranted in patients whose biopsy shows
mainly active changes while a primary biopsy showing pre-
dominantly chronic changes does not justify prolonged, ag-
gressive immunosuppressive treatment. The influence of
tubulointerstitial changes on clinical severity in patients with
HSN has also been addressed [20–22], and reports from sev-
eral authors have shown a discrepancy in the correlation be-
tween ISKDC grades and the outcome [13, 19, 23, 24]. Other
semiquantitative classifications evaluating multiple glomeru-
lar, tubulointerstitial and vascular parameters in addition to
our SQC have also been introduced for the histological eval-
uation of HSN [20, 22, 25–27], but they are not widely used in
clinical practice. The Oxford classification [28] was published
in 2009 as a histological classification for IgA nephropathy, a
disease which is histologically similar to HSN [29]. To our
knowledge, there have been no studies of the feasibility of
using the Oxford classification in the case of children with
HSP, although Kim et al. did suggest that it could be used
for predicting the long-term outcome in adult HSP patients
[30]. The main differences between the Oxford classification
and the SQC concern the number of histological parameters
evaluated, as the Oxford classification considers four variables
and the SQC takes into account a total of 14 variables. There
are also some pathophysiological differences between HSP
and IgA nephropathy. For example, onset of the disease is
typically more acute in HSP than in IgA nephropathy [31],
emphasizing the need for analysing the activity and chronicity
components separately.
We adopted here a modified version of the classification
used in our earlier work in which we found that the chronicity
index and the total biopsy score were the best histological
factors for predicting the outcome of patients with childhood
Fig. 3 aBox-plot of 24-h urine protein excretion at the time of the biopsy in relation to the three outcome groups, b box-plot of systolic blood pressure at
the time of the biopsy in relation to the three outcome groups. dU-Prot 24-h Urine protein excretion
Pediatr Nephrol (2017) 32:1201–1209 1207
IgA nephropathy [7]. For the purposes of the present study, the
classification was expanded to include evaluations of
mesangial proliferation, lobulation and focal or diffuse
mesangial proliferation and applied to a cohort of HSN pa-
tients. According to our analyses, the total biopsy score and
activity index were the best factors for predicting the outcome.
Both variables also tended to be better than ISKDC grades for
predicting patient outcome when expressed in terms of AUC
and AIC values. The importance of active lesions is under-
standable, since we were analysing primary kidney biopsies.
Other studies have also shown a correlation between the acu-
ity score of the primary biopsy and clinical severity [20] and
reported that active lesions are predictors of a poor outcome
[18]. The total biopsy score obtained in the SQC was also
useful for differentiating patients with favourable and
unfavourable outcomes, since those with a total biopsy score
of ≤10 points usually had a good prognosis [1/39 patients had
an unfavourable outcome (3%)], while those with a score of
≥11 had a greater risk of renal impairment [7/14 patients had
an unfavourable outcome (50%)].
Several authors have concluded that the long-term outcome
of HSN is determined by the severity of renal involvement at
the onset of the disease [3, 12, 13], a notion which is also
supported by our findings as the patients with an unfavourable
outcome had significantly higher dU-Prot than those with a
favourable outcome. In addition, long-term follow-up studies
of the prognosis for HSN have shown that clinical recovery
does not inevitably mean a favourable long-term outcome [12,
13, 32]. It is therefore possible that clinical deterioration will
occur even in our cohort of HSN patients in the future, since
the median follow-up time was only 7.3 years. Our patients
with an unfavourable outcome also had higher systolic blood
pressure at the time of the biopsy than those with a favourable
outcome, whereas other studies have failed to find initial hy-
pertension to be a predictor of a poor outcome in multivariate
regression analysis [24, 32]. One possible explanation for the
different results is that we analysed the absolute blood pres-
sure figures and did not categorize the patients into those with
or without hypertension.
There are a number of limitations to our findings. One, and
probably the most important, is the variability in treatment
within our cohort, which is undoubtedly a confounding factor.
It is also possible that the active nature of the treatment may
have hampered the overall prognostic value of the kidney
biopsies [19, 33]. Thirty-eight of our patients (72%) had re-
ceived immunosuppressive treatment for nephritis and 45
(85%) had received ACE/ARB medication for hypertension
and/or to control proteinuria. On the other hand, all eight pa-
tients with an unfavourable outcome had received immuno-
suppressive treatment and seven (88%) had received ACE/
ARB medication at some point in the treatment of their dis-
ease, although the immunosuppressive treatments used and
their timing and duration varied between patients. It is
therefore difficult to draw any conclusions on the influence
of treatment on patient outcome. Twenty-six patients had also
received oral prednisone or prednisolone for extrarenal symp-
toms before the biopsy, but we have previously shown that
early treatment with low-dose steroids does not prevent the
development of nephritis in HSP [34] and does not have an
effect on the frequency or timing of the nephritis [35]. Also,
even though there is bias due to the treatment, it does not
hamper the evaluation and comparison of the two classifica-
tions since the scorings were performed from the same biop-
sies obtained from the same patients and were then compared
against each other in their ability to predict the outcome.
Another limitation of this work is that we did not take into
account any confounding factors in the ROC curve and logis-
tic regression analyses. This is due to the small sample size,
and especially the small number of patients with an
unfavourable outcome which might bias logistic regression
results [36].
In conclusion, although a kidney biopsy is mandatory for
the diagnosis of HSN, its value as a predictor of the outcome is
dependent on many clinical variables, and also on the classi-
fication used. Our suggestion is that a semiquantitative classi-
fication including activity and chronicity indices should be
introduced into clinical practice. For this purpose, larger pro-
spective studies on the prognostic value of kidney biopsies for
the treatment of HSN patients are needed in order to evaluate
SQC and other scoring systems.
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